Navigation Links
CMC Biologics and Zymeworks Enter into Agreement for Process Development and Clinical Manufacture of Bi-Specific Antibody Product Candidate
Date:9/3/2014

SEATTLE and VANCOUVER, British Columbia, Sept. 3, 2014 /PRNewswire/ -- CMC Biologics, Inc., a global leader in process development and contract manufacturing, and Zymeworks Inc., a Canadian biotherapeutics company and a world leader in the development of antibody therapeutics, have entered into a Master Services Agreement for process development, formulation development and cGMP clinical manufacturing of a recombinant human IgG1 bi-specific (heterodimeric) antibody.

"Being selected by Zymeworks, who are known for developing best-in-class and highly effective protein therapeutics, is a natural fit for us and validates our technical excellence and partnering philosophy," said Gustavo Mahler, PhD, Global Chief Operations Officer of CMC Biologics. "Through this agreement, Zymeworks and CMC Biologics will work together to advance the next frontier of bi-specific antibody development platforms and bring novel therapies to patients in need."

"As we advance our lead Azymetric™ oncology program and first therapeutic built on our proprietary ZymeCAD™ platform, choosing a contract partner with a track record of success in development and manufacturing is critical," said Ali Tehrani, PhD, President and CEO of Zymeworks.  "Our collaboration with CMC Biologics helps position us to move our oncology program into clinical trials for the treatment of breast cancer and other solid tumors, as well as subsequent therapeutic candidates targeted towards hematological cancers such as leukemia and lymphoma."

About CMC Biologics
CMC Biologics is leading the industry among CMO's in reliability, technical excellence, and quality – Right and On Time. With three facilities in the USA and Europe, the Company provides fully integrated biopharmaceutical development and manufacturing solutions to clients globally. The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and commercial production. The Company's wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing. Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes. More detailed information can be found at www.cmcbiologics.com.

About Zymeworks Inc.
Zymeworks is a privately held biotherapeutics company that is developing best-in-class Azymetric™ bi‑specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. The company's novel Azymetric™ and AlbuCORE™ platforms, and its proprietary ZymeCAD™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. Zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. More information on Zymeworks can be found at www.zymeworks.com.

Logo - http://photos.prnewswire.com/prnh/20110502/SF93356LOGO
Logo - http://photos.prnewswire.com/prnh/20140902/142261


'/>"/>
SOURCE CMC Biologics
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
2. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
3. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
4. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
5. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
6. Chinese Compulsory Immunization Program for Livestock Creates Massive Opportunity for Animal Vaccines and Biologics Developers
7. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
8. Pinnacle Biologics and INTERmedic Medical Devices announce strategic manufacturing and distribution agreement for cancer laser technology
9. CMC Biologics Acquires XOMAs Bay Area Manufacturing Facility
10. Global Spinal Devices and Biologics Market 2011-2015
11. Synthetic Biologics Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)...  Medical professionals are expected to continuously ... their patients. Medical simulations offer clinicians the ... Simulation provides a safe method for teaching ... refine techniques and build confidence, without putting ... such as augmented reality, will now provide ...
(Date:9/5/2017)... -- Xyntek Inc. has announced another milestone in their continued growth and success of ... growing demands of customer engagements regionally.  ... Midwest office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest ... In ...
(Date:9/1/2017)... 1, 2017  Explorers Like Us ( https://explorerslikeus.com/ ) is ... experiences — and deliver these experiences as part of Life ... feel and heal better. ... While nothing beats a walk, jog or simply ... Life Environments™ is the next best thing when getting there ...
Breaking Medicine Technology:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... and Centers of Excellence (CoE) with the latest Artificial Intelligence (AI) thinking, announced ... presence offers quick and easy access to essential information that offers a more ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... and commercialization, has just released a new white paper discussing the benefits ... than ever about medical device, pharmaceutical, and combination product organizations making sure ...
(Date:9/20/2017)... ... ... Compliancy Group is proud to announce that its proprietary ... long-time client pass their Department of Health and Human Services (HHS) Office for ... the help of the Compliancy Group's Audit Response Program™, not a single client ...
(Date:9/20/2017)... ... 20, 2017 , ... The Centers for Medicare and Medicaid Services (CMS) stated ... to using only Worksheet S-10 to distribute Disproportionate Share Hospital (DSH) Uncompensated Care Payments ... complimentary webinars on October 17, 2017 at 2 P.M. EST and uncover how ...
(Date:9/20/2017)... ... 20, 2017 , ... “RECYCLED Ezekiel's Plan for Freedom from ... from ADDICTION” is the creation of published author, Bill Miller. Bill Miller ... services, including more than a decade of addiction to prescription drugs. He ...
Breaking Medicine News(10 mins):